pharma · Hepatitis C Virus Infection · Chronic Hepatitis B
Gilead Sciences Ireland
Gilead Sciences Ireland UC
Gilead Sciences is a pharma organization headquartered in Foster City, USA. Primary therapeutic focus areas include Hepatitis C Virus Infection, Chronic Hepatitis B, HIV-1-infection, HCV Infection, Crohn's Disease. NovaP
Company details
- Status
- Public
- HQ
- 333 Lakeside Drive, Foster City, CA 94404, US
- Founded
- 1987
- Employees
- 14,602
- Programs
- 26
- Drugs
- 17
- Patents
- 0
B/F/TAF
Phase 3 · small molecule · HIV-1/HBV Co-Infection
B/F/TAF for HIV-1/HBV Co-Infection is a Phase 3 program (small_molecule) at Gilead Sciences Ireland UC with 1 ClinicalTrials.gov record(s).
Internal code GS-US-380-4458
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Gilead Sciences Ireland UC
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- HIV-1/HBV Co-Infection
- Status
- completed
- Trials
- 1